Evidence map›Paper›PMID 33850736›Full record

ArticleTranslational andrology and urology2021

Identification and validation of a six immune-related gene signature for prediction of biochemical recurrence in localized prostate cancer following radical prostatectomy.

Jiaochen Luan, Qijie Zhang, Lebin Song, Yichun Wang, Chengjian Ji, Rong Cong, Qitong Zheng, Zhenggang Xu, Jiadong Xia, Ninghong Song

Abstract read
In one paragraph

Article in Translational andrology and urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiaochen LuanDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Qijie ZhangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Lebin SongDepartment of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yichun WangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Chengjian JiDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Rong CongDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Qitong ZhengHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhenggang XuHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jiadong XiaDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Ninghong SongDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer (PCa) is the second lethal heterogeneous cancer among males worldwide, and approximately 20% of PCa patients following radical prostatectomy (RP) will undergo biochemical recurrence (BCR). This study is aimed to identify the immune-related gene signature that can predict BCR in localized PCa following RP.

methodsExpression profile of genes together with clinical parameters from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus database (GEO) and the immune-related genes from the Molecular Signatures Database v4.0 were applied to construct and validate the gene signature. The Cox regression analyses were conducted to identify the candidate genes and establish the gene signature. To estimate the prognostic power of the risk score, the time-dependent receiver operating characteristic (ROC) analysis and Harrell's index of concordance (C-index) were utilized. We also established a nomogram to forecast the probability of patients' survival.

resultsA total of 268 patients from the TCGA and 77 patients from GSE70770 and six immune-related genes (

conclusionsThis signature could serve as an independent prognostic factor for BCR. Incorporation of our signature into traditional risk classification might further stratify patients with different prognosis, which could assist practitioners in developing clinical decision-making.

Indexed as

biochemical recurrence (BCR)immune-related gene signatureLocalized prostate cancerprognosis

Identifiers

PMID33850736
PMCPMC8039594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.